MABCAMPATH Side Effects

7018714-6 | Body Temperature Increased, Candida Sepsis, Lung Infiltration, Myelodysplastic Syndrome
on Aug 26, 2010 Male patient from UNITED STATES , 60 years of age, weighting 134.5 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: body temperature increased, candida sepsis, lung infiltration, myelodysplastic syndrome. Mabcampath dosage: Dose Escalation.

7014816-9 | Body Temperature Increased, Candida Sepsis, Lung Infiltration, Myelodysplastic Syndrome
Patient was taking Mabcampath (View Usage). Patient had the following side effects: body temperature increased, candida sepsis, lung infiltration, myelodysplastic syndrome on Aug 26, 2010 from UNITED STATES Additional patient health information: Male patient , 60 years of age, weighting 134.5 lb, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: Dose Escalation.

6933356-6 | Atrial Fibrillation
Adverse event was reported on Aug 11, 2010 by a Male patient taking Mabcampath (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 39 years of age, After Mabcampath was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?). During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6929527-5 | Atrial Fibrillation
on Aug 11, 2010 Male patient from UNITED STATES , 39 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?). Mabcampath dosage: . During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.


6856689-0 | Atrial Fibrillation
on Jul 15, 2010 Male patient from UNITED STATES , 39 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mabcampath (View Usage). Patient had the following side effects: atrial fibrillation (What is atrial fibrillation?). Mabcampath dosage: 2 Doses Received. During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6835252-1 | Campylobacter Infection, Guillain-barre Syndrome
Patient was taking Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: campylobacter infection, guillain-barre syndrome (What is guillain-barre syndrome?) on Jun 23, 2010 from UNITED STATES Additional patient health information: Male patient , 56 years of age, was diagnosed with t-cell prolymphocytic leukaemia and. Mabcampath dosage: Unit Dose: 10 Mg/ml. During the same period patient was treated with NEOFLUBIN (Unit Dose: 25 Mg/ml) (View Neoflubin Review and Neoflubin Label ), EBEXANTRON (Unit Dose: 2 Mg/ml) (View Ebexantron Review and Ebexantron Label ).

6835249-1 | Bone Marrow Failure, Bone Marrow Necrosis, Bone Pain, Febrile Infection, Neutropenia, Pancytopenia
Adverse event was reported on May 05, 2010 by a Female patient taking Mabcampath (View Usage) (Dosage: Intravenous And Subcutaneous Application) was diagnosed with b-cell small lymphocytic lymphoma stage iv, infection prophylaxis and. Location: GERMANY , 63 years of age, Patient experienced the following unwanted or unexpected effects: bone marrow failure, bone marrow necrosis, bone pain, febrile infection, neutropenia, pancytopenia. During the same period patient was treated with COTRIM (View Cotrim Review and Cotrim Label ), FAMCICLOVIR (View Famciclovir Review and Famciclovir Label ). Patient was hospitalized.

6822063-6 | Campylobacter Infection, Guillain-barre Syndrome
on Jun 23, 2010 Male patient from UNITED STATES , 56 years of age, was diagnosed with t-cell prolymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient had the following side effects: campylobacter infection, guillain-barre syndrome (What is guillain-barre syndrome?). Mabcampath dosage: Unit Dose: 10 Mg/ml. During the same period patient was treated with NEOFLUBIN (Unit Dose: 25 Mg/ml) (View Neoflubin Review and Neoflubin Label ), EBEXANTRON (Unit Dose: 2 Mg/ml) (View Ebexantron Review and Ebexantron Label ).

6817621-9 | Anaemia, Febrile Neutropenia, Multi-organ Failure, Sepsis, Septic Encephalopathy, Thrombocytopenia
on Jun 23, 2010 Male patient from GERMANY , 75 years of age, weighting 160.9 lb, was diagnosed with chronic lymphocytic leukaemia, antiviral prophylaxis, antibiotic prophylaxis, antifungal prophylaxis and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: anaemia, febrile neutropenia, multi-organ failure, sepsis (What is sepsis?), septic encephalopathy, thrombocytopenia. Mabcampath dosage: Total Daily Dose: 30 Mg. During the same period patient was treated with VALGANCICLOVIR (Total Daily Dose: 900 Mg) (View Valganciclovir Review and Valganciclovir Label ), COTRIM (Total Daily Dose: 1 Df) (View Cotrim Review and Cotrim Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6816606-6 | Anaemia, Febrile Neutropenia, Multi-organ Failure, Sepsis, Septic Encephalopathy, Thrombocytopenia
Patient was taking Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, febrile neutropenia, multi-organ failure, sepsis (What is sepsis?), septic encephalopathy, thrombocytopenia on Jun 23, 2010 from GERMANY Additional patient health information: Male patient , 75 years of age, weighting 160.9 lb, was diagnosed with chronic lymphocytic leukaemia, antiviral prophylaxis, antibiotic prophylaxis, antifungal prophylaxis and. Mabcampath dosage: Total Daily Dose: 30 Mg. During the same period patient was treated with VALGANCICLOVIR (Total Daily Dose: 900 Mg) (View Valganciclovir Review and Valganciclovir Label ), COTRIM (Total Daily Dose: 1 Df) (View Cotrim Review and Cotrim Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6765314-9 | Bone Marrow Necrosis, Bone Pain, Febrile Infection, Pancytopenia
Adverse event was reported on May 05, 2010 by a Female patient taking Mabcampath (View Usage) (Dosage: Intravenous And Subcutaneous Application) was diagnosed with b-cell small lymphocytic lymphoma stage iv, infection prophylaxis and. Location: GERMANY , 63 years of age, Patient had the following side effects: bone marrow necrosis, bone pain, febrile infection, pancytopenia. During the same period patient was treated with COTRIM (View Cotrim Review and Cotrim Label ), FAMCICLOVIR (View Famciclovir Review and Famciclovir Label ). Patient was hospitalized.

6765313-7 | Campylobacter Infection, Guillain-barre Syndrome
on May 26, 2010 Male patient from AUSTRIA , 56 years of age, was diagnosed with t-cell prolymphocytic leukaemia and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: campylobacter infection, guillain-barre syndrome (What is guillain-barre syndrome?). Mabcampath dosage: 10 Mg/ml Concentrate For Infusion Solution. During the same period patient was treated with NEOFLUBIN (25 Mg/ml Conctrate For Injection Or Infusion Solution) (View Neoflubin Review and Neoflubin Label ), EBEXANTRON (2 Mg/ml Conctrate For Infusion Solution) (View Ebexantron Review and Ebexantron Label ), ENDOXAN ^BAXTER^ (Unit Dose: 200 Mg) (View Endoxan ^baxter^ Review and Endoxan ^baxter^ Label ).

6763401-2 | Campylobacter Infection, Guillain-barre Syndrome
on May 26, 2010 Male patient from AUSTRIA , 56 years of age, was diagnosed with t-cell prolymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: campylobacter infection, guillain-barre syndrome (What is guillain-barre syndrome?). Mabcampath dosage: 10 Mg/ml Concentrate For Infusion Solution. During the same period patient was treated with NEOFLUBIN (25 Mg/ml Conctrate For Injection Or Infusion Solution) (View Neoflubin Review and Neoflubin Label ), EBEXANTRON (2 Mg/ml Conctrate For Infusion Solution) (View Ebexantron Review and Ebexantron Label ), ENDOXAN ^BAXTER^ (Unit Dose: 200 Mg) (View Endoxan ^baxter^ Review and Endoxan ^baxter^ Label ).

6617307-X | Asthenia, Decreased Appetite, Eastern Cooperative Oncology Group Performance Status Worsened
Patient was taking Mabcampath (View Usage). Patient had the following side effects: asthenia, decreased appetite, eastern cooperative oncology group performance status worsened on Dec 02, 2009 from FRANCE Additional patient health information: Female patient , 57 years of age, weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: As Used: 30 Mg. During the same period patient was treated with DEXAMETHASONE (As Used: 40 Mg) (View Dexamethasone Review and Dexamethasone Label ), PEGFILGRASTIM (As Used: 6 Mg) (View Pegfilgrastim Review and Pegfilgrastim Label ).

6615055-3 | Chronic Lymphocytic Leukaemia Transformation, Diffuse Large B-cell Lymphoma, Febrile Neutropenia, Pancytopenia, Pneumonia
Adverse event was reported on Apr 16, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: ) was diagnosed with chronic lymphocytic leukaemia and. Location: BELGIUM , 61 years of age, weighting 178.6 lb, After Mabcampath was administered, patient had the following side effects: chronic lymphocytic leukaemia transformation, diffuse large b-cell lymphoma, febrile neutropenia, pancytopenia, pneumonia (What is pneumonia?).

6593764-2 | Ascites, Disseminated Intravascular Coagulation
on Feb 11, 2010 Male patient from FRANCE , 61 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, disseminated intravascular coagulation. Mabcampath dosage: Cycle 1 Started One Week Prior To Onset. Patient was hospitalized.

6505278-6 | Arterial Thrombosis Limb, Induration, Intermittent Claudication, Pain In Extremity, Peripheral Ischaemia
on Dec 08, 2009 Male patient from FRANCE , 47 years of age, was diagnosed with chronic lymphocytic leukaemia, hypercholesterolaemia, hypertension, prophylaxis and was treated with Mabcampath (View Usage). Patient had the following side effects: arterial thrombosis limb, induration, intermittent claudication, pain in extremity, peripheral ischaemia. Mabcampath dosage: . During the same period patient was treated with TAHOR (View Tahor Review and Tahor Label ), AVLOCARDYL (View Avlocardyl Review and Avlocardyl Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), EFFERALGAN (3 G Per Day Between Cycles) (View Efferalgan Review and Efferalgan Label ). Patient was hospitalized.

6497522-9 | Asthenia, Decreased Appetite, Eastern Cooperative Oncology Group Performance Status Worsened
Patient was taking Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: asthenia, decreased appetite, eastern cooperative oncology group performance status worsened on Dec 02, 2009 from FRANCE Additional patient health information: Female patient , 57 years of age, weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: As Used: 30 Mg. During the same period patient was treated with DEXAMETHASONE TAB (As Used: 40 Mg) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), PEGFILGRASTIM (As Used: 6 Mg) (View Pegfilgrastim Review and Pegfilgrastim Label ). Patient was hospitalized.

6383689-X | Skin Cancer
Adverse event was reported on Aug 31, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: ) was diagnosed with chronic lymphocytic leukaemia and. Location: FRANCE , 65 years of age, Patient experienced the following unwanted or unexpected effects: skin cancer (What is skin cancer?). During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ).

6383688-8 | Skin Cancer
on Aug 31, 2009 Male patient from FRANCE , 65 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient had the following side effects: skin cancer (What is skin cancer?). Mabcampath dosage: . During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ).

6369742-5 | Campylobacter Infection, Chills, Cytomegalovirus Viraemia, Deep Vein Thrombosis, Diarrhoea, Pulmonary Embolism, Pyrexia, Sepsis
on Sep 10, 2009 Male patient from FRANCE , 55 years of age, weighting 191.8 lb, was diagnosed with chronic lymphocytic leukaemia, cytomegalovirus viraemia and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: campylobacter infection, chills, cytomegalovirus viraemia, deep vein thrombosis (What is deep vein thrombosis?), diarrhoea, pulmonary embolism (What is pulmonary embolism?), pyrexia, sepsis (What is sepsis?). Mabcampath dosage: As Used: 30 Mg. During the same period patient was treated with DEXAMETHASONE (As Used: 40 Mg) (View Dexamethasone Review and Dexamethasone Label ), WELLVONE (1 Spoonful In The Morning And Evening) (View Wellvone Review and Wellvone Label ), ZELITREX (1 In The Morning) (View Zelitrex Review and Zelitrex Label ), OXACILLIN (1 Million Units/day) (View Oxacillin Review and Oxacillin Label ), TARDYFERON (View Tardyferon Review and Tardyferon Label ), ROVALCYTE (Total Daily Dose: 1800 Mg) (View Rovalcyte Review and Rovalcyte Label ). Patient was hospitalized.

6349408-8 | Skin Cancer
Patient was taking Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: skin cancer (What is skin cancer?) on Aug 31, 2009 from FRANCE Additional patient health information: Male patient , 65 years of age, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: . During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ).

6349407-6 | Skin Cancer
Adverse event was reported on Aug 31, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: ) was diagnosed with chronic lymphocytic leukaemia and. Location: FRANCE , 65 years of age, Patient had the following side effects: skin cancer (What is skin cancer?). During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ).

6294518-7 | Asthenia, Decreased Appetite, Eastern Cooperative Oncology Group Performance Status Worsened
on Jul 17, 2009 Female patient from FRANCE , 57 years of age, weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: asthenia, decreased appetite, eastern cooperative oncology group performance status worsened. Mabcampath dosage: As Used: 30 Mg. During the same period patient was treated with DEXAMETHASONE (As Used: 40 Mg) (View Dexamethasone Review and Dexamethasone Label ), PEGFILGRASTIM (As Used: 6 Mg) (View Pegfilgrastim Review and Pegfilgrastim Label ). Patient was hospitalized.

6288622-7 | Asthenia, Decreased Appetite, Eastern Cooperative Oncology Group Performance Status Worsened
on Jul 17, 2009 Female patient from FRANCE , 57 years of age, weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, decreased appetite, eastern cooperative oncology group performance status worsened. Mabcampath dosage: As Used: 30 Mg. During the same period patient was treated with DEXAMETHASONE (As Used: 40 Mg) (View Dexamethasone Review and Dexamethasone Label ), PEGFILGRASTIM (As Used: 6 Mg) (View Pegfilgrastim Review and Pegfilgrastim Label ). Patient was hospitalized.

6273378-4 |
Patient was taking Mabcampath (View Usage). on Jul 15, 2009 from AUSTRIA Additional patient health information: Male patient , 49 years of age, weighting 167.6 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis and. Mabcampath dosage: 1x3mg/d, 4x10mg/d. During the same period patient was treated with DIBONDRIN (View Dibondrin Review and Dibondrin Label ), MEXALEN (View Mexalen Review and Mexalen Label ), RITUXIMAB (First-line R-chop) (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (First-line R-chop) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (First-line R-chop) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (First-line R-chop) (View Vincristine Review and Vincristine Label ), PREDNISOLONE (First-line R-chop) (View Prednisolone Review and Prednisolone Label ), METHYLPREDNISOLONE (High-dose Methylprednisolone (second Line Treatment)) (View Methylprednisolone Review and Methylprednisolone Label ).

6273267-5 | Cytomegalovirus Infection, Hepatic Necrosis, Leukopenia, Pyrexia
Adverse event was reported on Jul 09, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: Dose Escalation) was diagnosed with chronic lymphocytic leukaemia and. Location: ISRAEL , 72 years of age, After Mabcampath was administered, patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), hepatic necrosis, leukopenia, pyrexia. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), LEUKERAN (View Leukeran Review and Leukeran Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ). Patient was hospitalized.

6272235-7 |
on Jul 15, 2009 Male patient from AUSTRIA , 49 years of age, weighting 167.6 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis and was treated with Mabcampath (View Usage). . Mabcampath dosage: 1x3mg/d, 4x10mg/d. During the same period patient was treated with DIBONDRIN (View Dibondrin Review and Dibondrin Label ), MEXALEN (View Mexalen Review and Mexalen Label ), RITUXIMAB (First-line R-chop) (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (First-line R-chop) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (First-line R-chop) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (First-line R-chop) (View Vincristine Review and Vincristine Label ), PREDNISOLONE (First-line R-chop) (View Prednisolone Review and Prednisolone Label ), METHYLPREDNISOLONE (High-dose Methylprednisolone (second Line Treatment)) (View Methylprednisolone Review and Methylprednisolone Label ).

6269895-3 | Cytomegalovirus Infection, Hepatic Necrosis, Leukopenia, Pyrexia
on Jul 09, 2009 Male patient from ISRAEL , 72 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), hepatic necrosis, leukopenia, pyrexia. Mabcampath dosage: Dose Escalation. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), LEUKERAN (View Leukeran Review and Leukeran Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ). Patient was hospitalized.

6244241-X | Asthenia, Chills, Granulocytopenia, Haemoglobin Decreased, Hyperhidrosis, Hypersensitivity, Leukopenia, Myelodysplastic Syndrome, Pancytopenia
Patient was taking Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: asthenia, chills, granulocytopenia, haemoglobin decreased, hyperhidrosis, hypersensitivity, leukopenia, myelodysplastic syndrome, pancytopenia on May 31, 2009 from ISRAEL Additional patient health information: Male patient , 72 years of age, weighting 158.7 lb, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: As Used: 10 Mg. Patient was hospitalized and became disabled.

6219344-6 | Abdominal Distension, Ascites, Haemothorax, Oedema, Pleural Effusion, Skin Reaction
Adverse event was reported on Jun 05, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: ) was diagnosed with t-cell prolymphocytic leukaemia, restlessness, oedema and. Location: GERMANY , 65 years of age, weighting 138.9 lb, Patient experienced the following unwanted or unexpected effects: abdominal distension, ascites, haemothorax, oedema, pleural effusion, skin reaction. During the same period patient was treated with TAVOR (View Tavor Review and Tavor Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ).

6219307-0 | Blood Blister, Capillary Leak Syndrome, Confusional State, Disseminated Intravascular Coagulation, Febrile Bone Marrow Aplasia, Gingival Bleeding, Haematoma, Hypoxia
on May 29, 2009 Female patient from FRANCE , 70 years of age, weighting 121.3 lb, was diagnosed with t-cell prolymphocytic leukaemia, prophylaxis and was treated with Mabcampath (View Usage). Patient had the following side effects: blood blister, capillary leak syndrome, confusional state, disseminated intravascular coagulation, febrile bone marrow aplasia, gingival bleeding, haematoma, hypoxia. Mabcampath dosage: Total Daily Dose: 3 Mg. During the same period patient was treated with FLUDARA (4 Courses) (View Fludara Review and Fludara Label ), FASTURTEC (View Fasturtec Review and Fasturtec Label ), ENDOXAN (4 Courses) (View Endoxan Review and Endoxan Label ), CHLORAMINOPHENE (Total Daily Dose: 10 Mg) (View Chloraminophene Review and Chloraminophene Label ), SOLUPRED (Total Daily Dose: 20 Mg) (View Solupred Review and Solupred Label ). Patient was hospitalized.

6215998-9 | Asthenia, Chills, Granulocytopenia, Haemoglobin Decreased, Hyperhidrosis, Hypersensitivity, Leukopenia, Myelodysplastic Syndrome, Pancytopenia
on May 31, 2009 Male patient from ISRAEL , 72 years of age, weighting 158.7 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: asthenia, chills, granulocytopenia, haemoglobin decreased, hyperhidrosis, hypersensitivity, leukopenia, myelodysplastic syndrome, pancytopenia. Mabcampath dosage: As Used: 10 Mg. Patient was hospitalized and became disabled.

6215996-5 | Aggression, Coma, Disorientation
Patient was taking Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: aggression, coma, disorientation on Jun 03, 2009 from SERBIA Additional patient health information: Male patient , 65 years of age, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: As Used: 30 Mg. During the same period patient was treated with PRONISON (View Pronison Review and Pronison Label ), ENALAPRIL (Total Daily Dose: 10 Mg) (View Enalapril Review and Enalapril Label ).

6215964-3 | B-cell Lymphoma Stage Iv, Cytomegalovirus Infection, Multi-organ Failure
Adverse event was reported on May 27, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: As Used: 30 Mg/m2) was diagnosed with chronic lymphocytic leukaemia and. Location: ITALY , 53 years of age, Patient had the following side effects: b-cell lymphoma stage iv, cytomegalovirus infection (What is cytomegalovirus infection?), multi-organ failure. During the same period patient was treated with FLUDARABINE PHOSPHATE (Six Cycles Fcr) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

6214200-1 | Blood Blister, Capillary Leak Syndrome, Disseminated Intravascular Coagulation, Febrile Bone Marrow Aplasia, Gingival Bleeding, Haematoma, Injection Site Haemorrhage, Oliguria
on May 29, 2009 Female patient from FRANCE , 70 years of age, weighting 121.3 lb, was diagnosed with t-cell prolymphocytic leukaemia, prophylaxis and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: blood blister, capillary leak syndrome, disseminated intravascular coagulation, febrile bone marrow aplasia, gingival bleeding, haematoma, injection site haemorrhage, oliguria. Mabcampath dosage: Total Daily Dose: 3 Mg. During the same period patient was treated with FLUDARA (4 Courses) (View Fludara Review and Fludara Label ), FASTURTEC (View Fasturtec Review and Fasturtec Label ), ZYLORIC (View Zyloric Review and Zyloric Label ), ENDOXAN (4 Courses) (View Endoxan Review and Endoxan Label ), VALACYCLOVIR HCL (View Valacyclovir Hcl Review and Valacyclovir Hcl Label ), BACTRIM DS (View Bactrim Ds Review and Bactrim Ds Label ). Patient was hospitalized.

6212727-X | Alanine Aminotransferase Increased, Anaemia, Aspartate Aminotransferase Increased, B-cell Lymphoma, Blood Lactate Dehydrogenase Increased, Cytomegalovirus Infection, Epstein-barr Virus Infection, Hepatomegaly, Hypoalbuminaemia
on May 27, 2009 Male patient from ITALY , 53 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, b-cell lymphoma, blood lactate dehydrogenase increased, cytomegalovirus infection (What is cytomegalovirus infection?), epstein-barr virus infection, hepatomegaly, hypoalbuminaemia. Mabcampath dosage: As Used: 30 Mg/m2. During the same period patient was treated with FLUDARABINE PHOSPHATE (Six Cycles Fcr) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

6208227-3 | Anal Infection, Haemorrhagic Stroke
Patient was taking Mabcampath (View Usage). Patient had the following side effects: anal infection, haemorrhagic stroke on May 18, 2009 from FRANCE Additional patient health information: Male patient , 57 years of age, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: Cycles, On Treatment Days 1-3 Every 28 Days, 2 Cycles. During the same period patient was treated with FLUDARA (Cycles, On Treatment Days 1-3 Every 28 Days, 2 Cycles) (View Fludara Review and Fludara Label ), ENDOXAN (Cycles, On Treatment Days 1-3 Every 28 Days, 2 Cycles) (View Endoxan Review and Endoxan Label ), PLAVIX (View Plavix Review and Plavix Label ), EPO (View Epo Review and Epo Label ), RITUXIMAB (First Course Of R-chop) (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE W/VINCRISTINE/PREDNISONE (First Course Of R-chop) (View Cyclophosphamide W/vincristine/prednisone Review and Cyclophosphamide W/vincristine/prednisone Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ). Patient was hospitalized.

6203456-7 | Atrial Fibrillation
Adverse event was reported on May 14, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: 2 Doses Received) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 39 years of age, After Mabcampath was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?). During the same period patient was treated with OMEPRAZOL (View Omeprazol Review and Omeprazol Label ). Patient was hospitalized.

6201492-8 | Atrial Fibrillation
on May 14, 2009 Male patient from UNITED STATES , 39 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?). Mabcampath dosage: 2 Doses Received. During the same period patient was treated with OMEPRAZOL (View Omeprazol Review and Omeprazol Label ). Patient was hospitalized.

6201458-8 | Myelodysplastic Syndrome, Pancytopenia, Sepsis
on May 19, 2009 Female patient from ISRAEL , 72 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient had the following side effects: myelodysplastic syndrome, pancytopenia, sepsis (What is sepsis?). Mabcampath dosage: .

6199064-7 | Myelodysplastic Syndrome, Pancytopenia, Sepsis
Patient was taking Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: myelodysplastic syndrome, pancytopenia, sepsis (What is sepsis?) on May 19, 2009 from ISRAEL Additional patient health information: Female patient , 72 years of age, was diagnosed with chronic lymphocytic leukaemia and. Mabcampath dosage: .

6182441-8 | Abdominal Distension, Ascites, Haemothorax, Oedema, Pleural Effusion, Skin Reaction
Adverse event was reported on May 04, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: ) was diagnosed with t-cell prolymphocytic leukaemia, restlessness, oedema and. Location: GERMANY , 65 years of age, weighting 138.9 lb, Patient experienced the following unwanted or unexpected effects: abdominal distension, ascites, haemothorax, oedema, pleural effusion, skin reaction. During the same period patient was treated with TAVOR (View Tavor Review and Tavor Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ).

6167967-5 | Abdominal Pain Upper, Chronic Lymphocytic Leukaemia Transformation, Metastases To Liver, Neutropenia, Pancytopenia, Pyrexia
on Apr 17, 2009 Male patient from BELGIUM , 57 years of age, weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient had the following side effects: abdominal pain upper, chronic lymphocytic leukaemia transformation, metastases to liver, neutropenia, pancytopenia, pyrexia. Mabcampath dosage: . During the same period patient was treated with FLUDARA (4 Cycles) (View Fludara Review and Fludara Label ), SINTROM (View Sintrom Review and Sintrom Label ), ZOVIRAX (Total Daily Dose: 1600 Mg) (View Zovirax Review and Zovirax Label ), BACTRIM (View Bactrim Review and Bactrim Label ), CELEBREX (View Celebrex Review and Celebrex Label ), FLAGYL (View Flagyl Review and Flagyl Label ), ZANTAC (View Zantac Review and Zantac Label ). Patient was hospitalized.

6165050-6 | Chronic Lymphocytic Leukaemia Transformation, Diffuse Large B-cell Lymphoma, Febrile Neutropenia, Pancytopenia, Pneumonia
on Apr 16, 2009 Male patient from BELGIUM , 61 years of age, weighting 178.6 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: chronic lymphocytic leukaemia transformation, diffuse large b-cell lymphoma, febrile neutropenia, pancytopenia, pneumonia (What is pneumonia?). Mabcampath dosage: .

6152546-6 | Atrial Fibrillation
Patient was taking Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?) on Apr 02, 2009 from UNITED STATES Additional patient health information: Male patient , 39 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mabcampath dosage: 2 Doses Received. During the same period patient was treated with OMEPRAZOL (View Omeprazol Review and Omeprazol Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ).

6129984-0 | Acute Hepatic Failure, Cardiac Failure Congestive, Cd4 Lymphocytes Decreased, Chronic Lymphocytic Leukaemia Transformation, Cytomegalovirus Infection, Leukopenia, Lymphopenia, Metabolic Acidosis, Neutropenia
Adverse event was reported on Mar 20, 2009 by a Male patient taking Mabcampath (View Usage) (Dosage: 5 Cycles) was diagnosed with b-cell small lymphocytic lymphoma recurrent and. Location: FRANCE , 63 years of age, weighting 145.5 lb, Patient had the following side effects: acute hepatic failure, cardiac failure congestive, cd4 lymphocytes decreased, chronic lymphocytic leukaemia transformation, cytomegalovirus infection (What is cytomegalovirus infection?), leukopenia, lymphopenia, metabolic acidosis, neutropenia. During the same period patient was treated with FLUDARA (5 Cycles) (View Fludara Review and Fludara Label ), CYCLOPHOSPHAMIDE (5 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6110965-8 | Herpes Virus Infection
on Mar 02, 2009 Female patient from CANADA , 42 years of age, was diagnosed with t-cell chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). After Mabcampath was administered, patient had the following side effects: herpes virus infection. Mabcampath dosage: . Patient was hospitalized.

6099472-9 | Acute Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Cytomegalovirus Infection, Pancytopenia
on Feb 17, 2009 Male patient from AUSTRIA , 66 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Mabcampath (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection (What is cytomegalovirus infection?), pancytopenia. Mabcampath dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6088376-3 | Cardiopulmonary Failure, Hepatitis C, Sinusitis
Patient was taking Mabcampath (View Usage). Patient had the following side effects: cardiopulmonary failure, hepatitis c (What is hepatitis c?), sinusitis (What is sinusitis?) on Feb 16, 2009 from UNITED STATES Additional patient health information: Male patient , 68 years of age, was diagnosed with b-cell small lymphocytic lymphoma, infection prophylaxis, erosive duodenitis, diarrhoea, anaemia and. Mabcampath dosage: Unit Dose: 30 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (Unit Dose: 50 Mg) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), BISEPTOL (View Biseptol Review and Biseptol Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), HILAC FORTE (View Hilac-forte Review and Hilac-forte Label ), SORBIFER DURULES (View Sorbifer Durules Review and Sorbifer Durules Label ), EPREX (View Eprex Review and Eprex Label ), LOPERAMIDE HCL (View Loperamide Hcl Review and Loperamide Hcl Label ). Patient was hospitalized.